Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability

Christina RogalskiMedical Business Development, edia.con gemeinnützige GmbH, Leipzig, Saxony, GermanyBackground: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Rogalski C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/e8817301c9ba4248b8262399ef62c6be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e8817301c9ba4248b8262399ef62c6be
record_format	dspace
spelling	oai:doaj.org-article:e8817301c9ba4248b8262399ef62c6be2021-12-02T00:04:51ZCalcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability2230-326Xhttps://doaj.org/article/e8817301c9ba4248b8262399ef62c6be2015-06-01T00:00:00Zhttp://www.dovepress.com/calcipotriolbetamethasone-for-the-treatment-of-psoriasis-efficacy-safe-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XChristina RogalskiMedical Business Development, edia.con gemeinnützige GmbH, Leipzig, Saxony, GermanyBackground: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. This aspect was resolved when carefully designed vehicle components were invented (gel and ointment). This article reviews the efficacy, safety, and patient acceptability of calcipotriol/betamethasone dipropionate.Methods: A literature search of all articles published until February 2015 was performed, including the largest medical databases. The search strategy for evaluating the main topics of this review – efficacy, safety, and patient acceptability – was defined before checking the publications.Results: Seventy references were found and checked for relevance. For efficacy, the proportion of patients whose psoriasis improved was always significantly higher in the two-compound group compared to the group treated with the individual substances. In the context of safety, the fixed combination was generally associated with a lower risk of adverse events. In terms of patient acceptability, the fixed combination led to a significant improvement in quality of life. The two-compound product was more convenient to handle and time saving compared to former treatments.Conclusion: Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality.Keywords: psoriasis, calcipotriol/betamethasone, safety, efficacy, fixed combination, two-compound medicationRogalski CDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2015, Iss default, Pp 97-107 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 Rogalski C Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
description	Christina RogalskiMedical Business Development, edia.con gemeinnützige GmbH, Leipzig, Saxony, GermanyBackground: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. This aspect was resolved when carefully designed vehicle components were invented (gel and ointment). This article reviews the efficacy, safety, and patient acceptability of calcipotriol/betamethasone dipropionate.Methods: A literature search of all articles published until February 2015 was performed, including the largest medical databases. The search strategy for evaluating the main topics of this review – efficacy, safety, and patient acceptability – was defined before checking the publications.Results: Seventy references were found and checked for relevance. For efficacy, the proportion of patients whose psoriasis improved was always significantly higher in the two-compound group compared to the group treated with the individual substances. In the context of safety, the fixed combination was generally associated with a lower risk of adverse events. In terms of patient acceptability, the fixed combination led to a significant improvement in quality of life. The two-compound product was more convenient to handle and time saving compared to former treatments.Conclusion: Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality.Keywords: psoriasis, calcipotriol/betamethasone, safety, efficacy, fixed combination, two-compound medication
format	article
author	Rogalski C
author_facet	Rogalski C
author_sort	Rogalski C
title	Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_short	Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_full	Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_fullStr	Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_full_unstemmed	Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_sort	calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/e8817301c9ba4248b8262399ef62c6be
work_keys_str_mv	AT rogalskic calcipotriolbetamethasoneforthetreatmentofpsoriasisefficacysafetyandpatientacceptability
_version_	1718403958028894208

Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability

Ejemplares similares